Recombinant Human CDK4 Protein, GST-tagged, FITC conjugated

• Cat.No.: CDK4-758HF
• Product Overview: FITC conjugated recombinant human CDK4 (NP_000066.1) (Met 1-Glu 303), fused with the GST tag at the N-terminus, was produced in Baculovirus-Insect cells.

Specification

• Source: Insect cells
• Species: Human
• Tag: GST
• Form: Lyophilized
• Molecular Mass: The recombinant human CDK4/GST chimera consists of 528 amino acids and predicts a molecular mass of 60 kDa. It migrates as an approximately 55 kDa band in SDS-PAGE under reducing conditions.
• Protein length: 528
• Endotoxin: < 1.0 EU/ μg of the protein as determined by the LAL method.
• Characteristic: Disulfide-linked homodimer
  Labeled with FITC via amines
  Excitation source: 488 nm spectral line, argon-ion laser
  Excitation Wavelength: 488 nm
  Emission Wavelength: 535 nm
• Stability: Samples are stable for up to 12 months from date of receipt at -70 centigrade.
• Storage: Store it under sterile conditions at -20 to -70 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Storage Buffer: Lyophilized from sterile 50 mM Tris, 100 mM NaCl, 10% gly, 0.5 mM PMSF, pH 8.0
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4 centigrade before opening to recover the entire contents.

Gene Information

• Gene Name: CDK4 cyclin-dependent kinase 4 [ Homo sapiens ]
• Official Symbol: CDK4
• Gene ID: 1019
• mRNA Refseq: NM_000075
• Protein Refseq: NP_000066
• MIM: 123829
• UniProt ID: P11802

Reviews

02/18/2023

Whether it's troubleshooting experimental issues, providing guidance on experimental design, or answering any inquiries related to the CDK4 protein, the manufacturer is committed to helping researchers overcome challenges and achieve their scientific goals.

02/16/2020

They actively seek feedback and incorporate it into their product development process, continuously improving the quality and performance of the CDK4 protein.

05/29/2018

The manufacturer also values customer satisfaction and strives to maintain a strong relationship with researchers.

Q&As

Are there any potential challenges in targeting CDK4 for cancer therapy?

Resistance to CDK4 inhibitors and the need for patient stratification are some of the challenges in using CDK4 as a therapeutic target.

Can CDK4 be targeted for cancer therapy?

Yes, CDK4 is a target for cancer therapy, and drugs that inhibit CDK4 have been developed for the treatment of specific cancers.

How is CDK4 clinically relevant?

CDK4 is clinically relevant because it plays a crucial role in the development and progression of various cancers.

Which cancers are commonly associated with CDK4 overactivity?

CDK4 overactivity is commonly associated with breast cancer, melanoma, and liposarcoma.

How does CDK4 relate to cell senescence?

CDK4 can promote cell senescence, a state of irreversible growth arrest, which has implications in cancer therapy.